Sunshine Biopharma Inc. Held Annual Shareholder Meeting

Sunshine Biopharma Inc. held its annual shareholder meeting on December 11, 2025. Directors elected include Dr. Steve N. Slilaty, Mr. Camille Sebaaly, Dr. Rabi Kiderchah, Mr. David Natan, and Dr. Andrew Keller. Stockholders ratified M&K CPAS, PLLC as the independent accounting firm for 2025. An amendment to the 2023 Equity Incentive Plan to increase authorized shares to 683,000 was approved.

Sunshine Biopharma | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 9.417 M

Sunshine Biopharma Inc expected to post a loss of 13 cents a share - Earnings Preview

Sunshine Biopharma Inc is anticipated to report a quarterly revenue increase of 31.6%, reaching $11.1 million for the period ending September 30, 2025. However, the company is expected to incur a loss of 13 cents per share. The sole analyst rating for the stock is "buy," with a median 12-month price target of $7.00, significantly above its last closing price of $1.75.

Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)

Sunshine Biopharma (NASDAQ:SBFM) has received Health Canada authorization to market domperidone through its Nora Pharma subsidiary, marking a significant regulatory achievement. This approval opens access to a lucrative market, with global domperidone sales projected to reach $1.36 billion by the end of 2025, and Canada representing a $200 million opportunity. The company has a track record of regulatory success and is expanding its portfolio, with 72 generic drugs currently on the market and more planned for 2025. The recent announcement has led to a surge in trading volume for SBFM stock, indicating strong market interest.

Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea | SBFM Stock News

Sunshine Biopharma Inc. announced that its subsidiary, Nora Pharma Inc., has received Health Canada approval for Domperidone, a medication for cancer-related nausea. This approval marks a significant step in Sunshine Biopharma's expansion into the generic pharmaceuticals market. The North American Domperidone market is projected to grow from $533 million in 2025 to $781 million by 2033. CEO Dr. Steve Slilaty emphasized the importance of this approval in enhancing patient access to effective treatments.